Allakos Inc (ALLK) Given $64.00 Consensus Price Target by Analysts

Shares of Allakos Inc (NASDAQ:ALLK) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy rating.

Brokers have set a 12-month consensus target price of $64.00 for the company and are expecting that the company will post ($0.35) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Allakos an industry rank of 60 out of 255 based on the ratings given to related companies.

Separately, Zacks Investment Research cut Allakos from a “hold” rating to a “sell” rating in a research note on Wednesday, December 19th.

Shares of NASDAQ:ALLK opened at $38.95 on Tuesday. Allakos has a 12-month low of $26.00 and a 12-month high of $65.48.

In other news, Director John P. Mckearn sold 142,219 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $34.49, for a total transaction of $4,905,133.31. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Venture Fund (Ohi Rivervest II sold 52,837 shares of the firm’s stock in a transaction dated Thursday, January 24th. The shares were sold at an average price of $42.63, for a total value of $2,252,441.31. The disclosure for this sale can be found here.

Several hedge funds and other institutional investors have recently bought and sold shares of ALLK. Legal & General Group Plc bought a new stake in shares of Allakos in the third quarter worth about $56,000. Great West Life Assurance Co. Can bought a new stake in shares of Allakos in the fourth quarter worth about $89,000. Metropolitan Life Insurance Co. NY grew its stake in shares of Allakos by 203.1% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 2,961 shares of the company’s stock worth $155,000 after purchasing an additional 1,984 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Allakos by 264.0% in the fourth quarter. Bank of America Corp DE now owns 4,153 shares of the company’s stock worth $217,000 after purchasing an additional 3,012 shares during the last quarter. Finally, American International Group Inc. bought a new stake in shares of Allakos in the third quarter worth about $247,000. 40.31% of the stock is currently owned by institutional investors.

About Allakos

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Further Reading: Diversification in Your Portfolio

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.